Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S (2TZ) AI Stock Analysis

Top Page

DE:2TZ

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S

(Frankfurt:2TZ)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Very Low LeverageExtremely low debt reduces refinancing and solvency risk, preserving capacity to fund operations, product development and distributions through weaker cycles. Solid equity and positive returns add resilience without dependence on leverage.
Negative Factors
Revenue ContractionTTM revenue is contracting, while the broader revenue-growth measure is negative. Persistent top-line pressure would constrain operating leverage, distribution scale and the funds available for product investment.

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S (2TZ) vs. iShares MSCI Germany ETF (EWG)

-10%0%10%20%30%40%DE:2TZ+18.37%EWG+4.43%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
EUR 3.54B
Dividend Yield
26.06%
Average Volume (3M)
549
Price to Earnings (P/E)
36.6
Beta (1Y)
0.02
Revenue Growth
―
EPS Growth
―
Country
Germany
Employees
3,890
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S Business Overview & Revenue Model

Company Description

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (TPDRTG), a prominent pharmaceutical group operating with its various subsidiaries, primarily serves the People's Republic of China. Its core focus lies in the production and sale of tradit...

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

DE:2TZ against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
SG:42CSG:42C51NeutralSGD 558.96M-61.45-81.85%―3.27%43.59%
SG:8YYSG:8YY40UnderperformSGD 41.60M-12.63-181.49%―――

* General Sector Average

Performance Comparison

0%200%400%DE:2TZSG:1J5SG:42CSG:546SG:8YYSG:BFKDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
DE:2TZ and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:2TZTianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S2.300.3316.69%
SG:1J5Hyphens Pharma International Ltd.0.360.024.65%
SG:42CiX Biopharma Ltd.0.510.40355.36%
SG:546Medtecs International Corporation Ltd.0.10-0.02-18.40%
SG:8YYBiolidics Ltd.0.020.004.35%
SG:BFKPharmesis International Ltd.0.10-0.28-73.96%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.